The 5-HT2C receptor agonist WAY-163909 decreases impulsivity in the 5-choice serial reaction time test

Rachel Navarra; Thomas A. Comery; Radka Graf; Sharon Rosenzweig-Lipson; Mark Day

doi:10.1016/j.bbr.2007.11.016

The 5-HT_2C receptor agonist WAY-163909 decreases impulsivity in the 5-choice serial reaction time test

Rachel Navarra, Thomas A. Comery, Radka Graf, Sharon Rosenzweig-Lipson, Mark Day

Research output: Contribution to journal › Article › peer-review

53 Scopus citations

Abstract

Increased impulsivity is observed across a number of neuropsychiatric and neurodegenerative diseases. Preclinical evidence has demonstrated that antagonism of the serotonin 5-HT_2C receptor may act to increase impulsivity, leading to the hypothesis that an agonist may exert reciprocal effects and attenuate impulsive behavior [1]. The 5-HT_2C agonist, WAY-163909, was evaluated in the present paper using a variable stimulus duration and inter-trial interval manipulation in the 5-choice serial reaction time test designed to increase impulsivity and decrease attention. WAY-163909 treatment selectively and dose-dependently decreased impulsivity suggesting that agonism of the 5-HT_2C receptor may be useful for modulating impulsivity in disease states where impulsivity is a pathological feature.

Original language	English (US)
Pages (from-to)	412-415
Number of pages	4
Journal	Behavioural Brain Research
Volume	188
Issue number	2
DOIs	https://doi.org/10.1016/j.bbr.2007.11.016
State	Published - Apr 9 2008
Externally published	Yes

All Science Journal Classification (ASJC) codes

Behavioral Neuroscience

Access to Document

10.1016/j.bbr.2007.11.016

Cite this

@article{0e438fbd82624425af1eab4d714d8879,

title = "The 5-HT2C receptor agonist WAY-163909 decreases impulsivity in the 5-choice serial reaction time test",

abstract = "Increased impulsivity is observed across a number of neuropsychiatric and neurodegenerative diseases. Preclinical evidence has demonstrated that antagonism of the serotonin 5-HT2C receptor may act to increase impulsivity, leading to the hypothesis that an agonist may exert reciprocal effects and attenuate impulsive behavior [1]. The 5-HT2C agonist, WAY-163909, was evaluated in the present paper using a variable stimulus duration and inter-trial interval manipulation in the 5-choice serial reaction time test designed to increase impulsivity and decrease attention. WAY-163909 treatment selectively and dose-dependently decreased impulsivity suggesting that agonism of the 5-HT2C receptor may be useful for modulating impulsivity in disease states where impulsivity is a pathological feature.",

author = "Rachel Navarra and Comery, {Thomas A.} and Radka Graf and Sharon Rosenzweig-Lipson and Mark Day",

year = "2008",

month = apr,

day = "9",

doi = "10.1016/j.bbr.2007.11.016",

language = "English (US)",

volume = "188",

pages = "412--415",

journal = "Behavioural Brain Research",

issn = "0166-4328",

publisher = "Elsevier B.V.",

number = "2",

}

TY - JOUR

T1 - The 5-HT2C receptor agonist WAY-163909 decreases impulsivity in the 5-choice serial reaction time test

AU - Navarra, Rachel

AU - Comery, Thomas A.

AU - Graf, Radka

AU - Rosenzweig-Lipson, Sharon

AU - Day, Mark

PY - 2008/4/9

Y1 - 2008/4/9

N2 - Increased impulsivity is observed across a number of neuropsychiatric and neurodegenerative diseases. Preclinical evidence has demonstrated that antagonism of the serotonin 5-HT2C receptor may act to increase impulsivity, leading to the hypothesis that an agonist may exert reciprocal effects and attenuate impulsive behavior [1]. The 5-HT2C agonist, WAY-163909, was evaluated in the present paper using a variable stimulus duration and inter-trial interval manipulation in the 5-choice serial reaction time test designed to increase impulsivity and decrease attention. WAY-163909 treatment selectively and dose-dependently decreased impulsivity suggesting that agonism of the 5-HT2C receptor may be useful for modulating impulsivity in disease states where impulsivity is a pathological feature.

AB - Increased impulsivity is observed across a number of neuropsychiatric and neurodegenerative diseases. Preclinical evidence has demonstrated that antagonism of the serotonin 5-HT2C receptor may act to increase impulsivity, leading to the hypothesis that an agonist may exert reciprocal effects and attenuate impulsive behavior [1]. The 5-HT2C agonist, WAY-163909, was evaluated in the present paper using a variable stimulus duration and inter-trial interval manipulation in the 5-choice serial reaction time test designed to increase impulsivity and decrease attention. WAY-163909 treatment selectively and dose-dependently decreased impulsivity suggesting that agonism of the 5-HT2C receptor may be useful for modulating impulsivity in disease states where impulsivity is a pathological feature.

UR - http://www.scopus.com/inward/record.url?scp=39149139621&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39149139621&partnerID=8YFLogxK

U2 - 10.1016/j.bbr.2007.11.016

DO - 10.1016/j.bbr.2007.11.016

M3 - Article

C2 - 18191235

AN - SCOPUS:39149139621

SN - 0166-4328

VL - 188

SP - 412

EP - 415

JO - Behavioural Brain Research

JF - Behavioural Brain Research

IS - 2

ER -

The 5-HT_2C receptor agonist WAY-163909 decreases impulsivity in the 5-choice serial reaction time test

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this